Novo Nordisk announces impact from Volume Based Procurement for insulin in China
November 26 2021 - 1:06AM
Novo Nordisk announces impact from Volume Based Procurement for
insulin in China
Bagsværd,
Denmark,
26 November 2021 – Novo Nordisk
today announced that the company has received the results from the
Volume Based Procurement (VBP) tender for insulin in China. The
Chinese National Healthcare Security Administration has tendered
insulin sold at hospitals, and Novo Nordisk has participated in the
tender. All Novo Nordisk’s insulin were included in the tender
except for Ryzodeg® and Xultophy®.
Novo Nordisk currently expects an estimated negative impact on
global sales growth of around 3% in 2022 as a result of reduced
prices and reduced volumes of insulin sold in China. The VBP for
insulin is expected to be implemented during the first half of
2022.
Novo Nordisk will provide the financial outlook for 2022 in
connection with the announcement of the full-year 2021 results on 2
February 2022.
About Novo NordiskNovo Nordisk is a leading
global healthcare company, founded in 1923 and headquartered in
Denmark. Our purpose is to drive change to defeat diabetes and
other serious chronic diseases such as obesity and rare blood and
endocrine disorders. We do so by pioneering scientific
breakthroughs, expanding access to our medicines and working to
prevent and ultimately cure disease. Novo Nordisk employs about
47,000 people in 80 countries and markets its products in around
170 countries. Novo Nordisk's B shares are listed on Nasdaq
Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO).
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 3079 3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
David Heiberg
Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
Mark Joseph Root
(US) |
+1 848 213
3219 |
mjhr@novonordisk.com |
Company announcement No 76 / 2021
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024